ALIVUSNSEQ3 FY23January 27, 2023

Alivus Life Sciences Limited

2,242words
1turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
anuary 27, 2023 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 To, The Manager - Listing, National Stock Exchange of Indi
3.5%
t of delivering steady growth with stable margins in the coming quarters.” ( IN ₹ MILLION S) 5,407 3.5% REVENUE YoY 6.2% QoQ ( IN ₹ MILLION S) 1,521 1.6% EBITDA YoY (1.0%) QoQ • GLS registered a re
6.2%
ady growth with stable margins in the coming quarters.” ( IN ₹ MILLION S) 5,407 3.5% REVENUE YoY 6.2% QoQ ( IN ₹ MILLION S) 1,521 1.6% EBITDA YoY (1.0%) QoQ • GLS registered a revenue of ₹ 5,407 Mn
1.6%
the coming quarters.” ( IN ₹ MILLION S) 5,407 3.5% REVENUE YoY 6.2% QoQ ( IN ₹ MILLION S) 1,521 1.6% EBITDA YoY (1.0%) QoQ • GLS registered a revenue of ₹ 5,407 Mn for Q3 FY23 from operations, reco
1.0%
.” ( IN ₹ MILLION S) 5,407 3.5% REVENUE YoY 6.2% QoQ ( IN ₹ MILLION S) 1,521 1.6% EBITDA YoY (1.0%) QoQ • GLS registered a revenue of ₹ 5,407 Mn for Q3 FY23 from operations, recording a growth of
₹ 5,407
YoY 6.2% QoQ ( IN ₹ MILLION S) 1,521 1.6% EBITDA YoY (1.0%) QoQ • GLS registered a revenue of ₹ 5,407 Mn for Q3 FY23 from operations, recording a growth of 6.2% QoQ and growth of 3.5% YoY. • Externa
2%
2% QoQ and growth of 3.5% YoY. • External business (ex-GPL) continue to see good traction growing 2% QoQ and 24% YoY driven by regulated markets • GPL business saw strong recovery of 19% on sequenti
24%
growth of 3.5% YoY. • External business (ex-GPL) continue to see good traction growing 2% QoQ and 24% YoY driven by regulated markets • GPL business saw strong recovery of 19% on sequential basis •
19%
tion growing 2% QoQ and 24% YoY driven by regulated markets • GPL business saw strong recovery of 19% on sequential basis • Gross Margins are at 51.0 %, up 20 bps YoY driven by product mix and PLI sch
51.0 %
ated markets • GPL business saw strong recovery of 19% on sequential basis • Gross Margins are at 51.0 %, up 20 bps YoY driven by product mix and PLI scheme benefit ( IN ₹ MILLION S) 1,050 1.2% PAT YoY
20 bps
s • GPL business saw strong recovery of 19% on sequential basis • Gross Margins are at 51.0 %, up 20 bps YoY driven by product mix and PLI scheme benefit ( IN ₹ MILLION S) 1,050 1.2% PAT YoY (1.8%) QoQ
1.2%
are at 51.0 %, up 20 bps YoY driven by product mix and PLI scheme benefit ( IN ₹ MILLION S) 1,050 1.2% PAT YoY (1.8%) QoQ • EBITDA margins at 28.1% remain steady on YoY basis, with a slight sequenti
Speaking time
REGISTERED OFFICE
1
Advertisement
Opening remarks
REGISTERED OFFICE
T: 91 22 68297979 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. CIN: U74900PN2011PLC139963 Website: www.glenmarklifesciences.com 19
Advertisement
← All transcriptsALIVUS stock page →